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Abstract In the field of thrombosis and haemostasis, many
preanalytical variables influence the results of coagulation
assays and measures to limit potential results variations
should be taken. To our knowledge, no paper describing the
development and maintenance of a haemostasis biobank has
been previously published. Our description of the biobank of
the Swiss cohort of elderly patients with venous thrombo-
embolism (SWITCO65?) is intended to facilitate the set-up
of other biobanks in the field of thrombosis and haemostasis.
SWITCO65? is a multicentre cohort that prospectively
enrolled consecutive patients aged C65 years with venous
thromboembolism at nine Swiss hospitals from 09/2009 to 03/
2012. Patients will be followed up until December 2013. The
cohort includes a biobank with biological material from each
participant taken at baseline and after 12 months of follow-
up. Whole blood from all participants is assayed with a
standard haematology panel, for which fresh samples are
required. Two buffy coat vials, one PAXgene Blood RNA
System tube and one EDTA-whole blood sample are also
collected at baseline for RNA/DNA extraction. Blood sam-
ples are processed and vialed within 1 h of collection and
transported in batches to a central laboratory where they are
stored in ultra-low temperature archives. All analyses of the
same type are performed in the same laboratory in batches.
Using multiple core laboratories increased the speed of
sample analyses and reduced storage time. After recruiting,
processing and analyzing the blood of more than 1,000
patients, we determined that the adopted methods and tech-
nologies were fit-for-purpose and robust.
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Introduction
Biobanking is increasingly common because researchers
recognize that large samples are often required to identify
the molecular or genetic basis of complex diseases.
Establishing a biobank is a multidisciplinary task that
requires extensive knowledge of preanalytical, analytical
and storage procedures, as well as expertise in data man-
agement, and related ethical concerns [1, 2].
Study-based biobanks are developed in relation to
specific research questions; thus biobanks take various
approaches and use different designs. An examination of
the designs and methodology of biobanks across the globe
may provide information regarding best practices in design
and methodology [3–6].
In the field of haemostasis, many preanalytical variables
influence the results of coagulation assays, such as factors
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V and VIII, and may affect the quality of the subsequent
results. Therefore, methods to limit these variations of
results should be foreseen when building a biobank in the
field of haemostasis. To our knowledge, no study
describing the management of a biobank in the field of
haemostasis and thrombosis has yet been published.
Moreover, a biobank of biological material from venous
thromboembolism (VTE) patients is essential for transla-
tional research aiming to better characterize VTE at several
levels ranging from diagnostic and prognostic classification
to prediction of response to therapy.
Our detailed description of the biobank of the Swiss
cohort of elderly patients with venous thromboembolism
(SWITCO65?) is thus intended to facilitate set-up of other
biobanks in the field of haemostasis and thrombosis and to
contribute substantially to the discussion of good practice
and standard operating procedure (SOP).
Materials and methods
SWITCO65? is a prospective multicenter cohort study of
patients aged 65 years or older with acute VTE. The goal
of SWITCO65? is to determine the clinical and biological
factors and processes of care that drive long-term medical
outcomes, health-related quality of life, and medical
resource utilization for elderly patients with acute VTE.
Establishment of a biobank to collect and store serum,
plasma, DNA, and RNA samples was part of this project,
enabling future exploration of currently unknown biologi-
cal prognostic markers for VTE and treatment responses.
The methods of SWITCO65? cohort study have already
been described in detail elsewhere [7].
SWITCO65? participants
Five university and four high-volume non-university hos-
pitals in Switzerland participate in SWITCO65?. In- and
outpatients aged C65 years with an objective diagnosis of
VTE were eligible for inclusion.
Ethical considerations
Potentially eligible patients were approached for informed
consent to participate in the study. Trained study nurses
explained the study to each potentially eligible patient in a
face-to-face interview. In addition, patients were provided
an information form. The information was written in
French or German using plain language. At the time of
consent, patients were given a copy of both the information
and the signed consent forms and were asked whether they
had any questions. Because elderly patients may need more
time to understand consent information, information was
repeated if necessary to improve patient comprehension of
consent information [8, 9]. In fact, spending more time
talking one-on-one with potentially eligible patients was
shown to be the most effective way of improving study
patients’ understanding [10]. Final decision on the validity
of the patient’s consent was left to the study nurse.
Because general consent that permits all future uses of
blood samples was ethically unacceptable, patients were
separately asked for permission for future use of biological
samples for VTE-related genetic analyses only, and for
long-term preservation of samples (up to 20 years, per-
mitted by the local ethical committees), with the provision
that investigators obtain specific consent for any future use
unrelated to VTE (tiered consent) [11].
To guarantee donor confidentiality during sample ship-
ment and storage, all patient blood samples were reversibly
anonymized immediately after venipuncture. Patient blood
samples were labelled with a unique, computer-generated
serial number that did not include any personal identifiers
on blood sample tubes or cryovials.
Patients who refused to provide samples for future
genetic analyses could still participate in the clinical aspect
of the study and give blood samples for other purposes than
genetic analyses. Patients had the right to withdraw their
consent at any time. If they decided to withdraw, they were
asked whether they wanted their blood samples to be
destroyed or if they permitted continued use of their data
and blood samples.
The study protocol and the biobank project were both
approved by ethics committees at all participating hospitals
and followed the recommendations of the Swiss Academy
of Medical Sciences (http://www.samw.ch/en/Ethics/Guide
lines/Currently-valid-guidelines.html) and those published
in the literature (http://www.isber.org/Pubs/BestPractices
2008.pdf) [2, 6].
Baseline sample and data collection
All consenting patients underwent blood sampling on the
day of enrolment. A total of 85 ml of blood were collected
from each patient, in 12 tubes (11 Sarstedt, Numbrecht,
Germany and 1 Paxgene Blood RNA System tube, Pre-
AnalytiX, Qiagen, Hilden, Germany), additional data are
provided in an online supplement. Because we used a
winged collection system, we took citrated plasma tubes in
second position to avoid contamination of citrated plasma
used for coagulations assays by tissue thromboplastin [12].
To measure prognostic biomarkers (ultra sensitive troponin
T, N-terminal proBrain Natriuretic Peptide, ultrasensitive
CRP), we used only blood samples collected within 24 h of
the index VTE event (Table 1).
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Follow-up sample and data collection
Since D-dimer, fibrinogen, antithrombin, protein C, protein S,
antiphospholipid antibodies, and factor VIII, IX, and XI levels
may be influenced by the presence of acute thrombosis or
ongoing anticoagulation, these parameters were determined
in a second fasting blood sample of 20 ml at 12 months after
the index VTE. Vitamin K dependent coagulation factors
(protein C, protein S, and factor IX) were not measured in
patients who were still receiving vitamin K antagonists.
Preanalytical procedures
Control of preanalytical variables is critical for coagulation
testing and to ensure clinical reliability of the results [13,
14]. All participating centers were provided with the nec-
essary material for blood collection and storage: ready-to-
use kits in plastic bags (one ready-to-use kit per patient).
Each kit contained two multi-sampling needles with a pre-
assembled holder (Multifly-Set, Sarstedt, Nu¨mbrecht);
adaptators for PAXgene Blood RNA System tubes
(Adaptator Luer, Becton–Dickinson AG, Basel); pre-
labeled blood collection tubes and storage cryovials with
polyester cryoresistant labels (EPI, West Sussex, UK); and
pre-labeled plastic bags for storage. Blood samples were
drawn after minimal venostasis with a 21-gauge needle
which is appropriate for use on elderly patients. Because
we used blood collection tubes from Sarstedt and Qiagen,
multi-sampling needles were required to permit a single
venipuncture for drawing blood through a winged collec-
tion system (a second needle was provided as rescue).
Data and sample management
We used an interactive, password-secured, web-based
database for data and sample management of the SWIT-
CO65? cohort study and biobank, ensuring the server was
secure for storage of epidemiological and clinical data
(Fig. 1). The web-based data management system auto-
matically generated a unique patient screening number for
each enrolled patient. This screening number could be
linked to a unique biobank number printed on the label of
the plastic bag of the ready-to-use kit. Specimens could be
traced through a protected reversible link to the database. To
avoid typographical errors and to allow rapid and secure
entry of the biobank number in the web database, numbers
were transcribed into barcodes and scanned into the database
with a commercial barcode scanner. The material for base-
line and 12-month blood samples was provided in blue and
red-labeled plastic bags, respectively. By this method, pre-
labelled bags containing prelabelled material for blood col-
lections were prepared centrally and in advance. Thus, we
could match the screening numbers of consecutive patients
recruited in a single hospital to their biobank numbers.
To avoid errors in the prenanalytical and analytical
phases, we chose to prelabel the blood collection tubes and
cryovials with cryoresistant labels and used a colour code
for labels and cryovial caps. Because barcoding is effective
for reducing identification errors and has been recom-
mended as an evidence-based ‘‘best practice’’ [15], we
decided to print an individual 8-digit European Article
Number (EAN8) barcode on all labels (Fig. 2). The first
digit referred to time point one or two; i.e., baseline or 12-
months follow-up. Digits two through five referenced the
individual patient biobank number. The sixth digit referred
to the cryovial type code, and the seventh digit referred to
the number of cryovials processed. The eighth digit was a
standard check number to verify whether the previous
Table 1 Planned laboratory analyses within the SWITCO65? cohort
study
Baseline
D-dimer ELISA (Vidas)
Fibrinogen
Factor V Leiden mutation
Prothrombin G20210A mutation
N-terminal proBrain natriuretic peptide
Genotyping cytochrome P450 2C9 (CYP2C9)
Genotyping vitamin K epoxide reductase complex subunit 1
(VKORC1)
Ultrasensitive troponin T
Growth arrest-specific gene 6 product (Gas6)
Thrombin generation
Prekallikrein
Cystatin C levels
Ultrasensitive C-reactive protein
Factor IX propeptide mutation
After 12 months follow-up
D-dimer ELISA (Vidas)
Fibrinogen
Antithrombin
Protein C
Protein S
Lupus anticoagulant
Anti-beta 2-glycoprotein I antibodies
Anticardiolipin antibodies
Homocystein
Factor VIII
Factor IX
Factor XI
Growth arrest-specific gene 6 product (Gas6)
Thrombin generation
Ultrasensitive C-reactive protein
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seven numbers were correct, according to a check digit
algorithm. SOPs pertaining to each aspect of the SWIT-
CO65? cohort study and biobank were developed and are
available on the study website (www.switco65.ch).
Quality control checks of sample handling, storing, and
laboratory procedures are performed regularly. The elec-
tronic biobank database has automatic checks for patient
identification, data completeness, and plausibility, and
allows accurate tracking of any individual blood sample.
Processing of blood samples
Trained study nurses processed blood samples at each
center according to the SWITCO65? SOPs. Aliquots of
samples were cryovialed in 3 ml polypropylene tubes with
screw caps (Sarstedt). Screw cap colors were assigned to
designate the content of the cryovials: black for EDTA
whole blood, blue for buffy coat, red for EDTA platelet
poor plasma (PPP), green for citrated PPP, yellow for
heparin PPP and white for serum. Blood collection tubes
selected for plasma or serum isolation were centrifuged for
10 min at 2,7009g. To simplify blood processing, we
chose one speed: 2,7009g was selected because of its
possible application to the centrifugation equipment of all
participating centers. Evidence suggests that increasing the
relative centrifugation forces and reducing the centrifuga-
tion time is possible without affecting the reliability of
coagulation testing [16–18]. The supernatant plasma from
citrated blood samples was re-centrifuged for 10 min at
2,7009g to remove remaining platelets [19]. The resulting
PPP was cryovialed within 1 h of blood collection and
immediately stored at -80 C in the local analytical lab-
oratory. We completed the blood processing within 1 h of
blood collection to avoid significant measurement variation
[20]. In fact a recent study observed clinically significant
changes, defined as a percentage change of more than 10 %
SWITCO65+ study
informed consent
Venipuncture
At baseline :      12 tubes 
At 12 months :    4 tubes
Scanning of the biobank number present on the ready-to-
use blood samples kit and linkage to the patient screening 
number generated by the database
Secured web-based database
Separation of blood samples
Blood processed within 1 hour (except
EDTA-WB) to obtain cryovials of EDTA-PPP, 
citrated-PPP, heparin-PPP, BF, EDTA-WB, 
and serum
Cryovials stored at -80°C at
each participating center
Cryovials shipped from participating
centers to the SWITCO65+ biobank
Each barcoded cryovial scanned into the database
Cryovials arriving at the 
SWITCO65+ biobank
20 cryovials per patient 
containing: EDTA-PPP, 
citrated-PPP, heparin-PPP, 
BF, EDTA-WB, serum,  
and 1 RNA special tube
17 cryovials per patient 
containing: EDTA-PPP, 
EDTA-WB, citrated-PPP, 
heparin-PPP, and serum
Short term storage
at -80°C in 0.5-2 ml cryovials
Generation of a patient 
screening number
Long term storage
at -80°C in 0.5-2 ml cryovials
SWITCO65+ study analyses
Fig. 1 Processing and storage of blood samples. For each enrolled
patient, the web-based data management system automatically
generates a unique patient screening number. The patient screening
number is then linked to a biobank number. After collection, blood
samples are processed and stored at each participating center, at -80
Celsius within 1 h. Cryovials are shipped to the central SWITCO65?
biobank in batches. Upon arrival at the SWITCO65? biobank,
cryovials are separated in two groups: long-term and short-term
storage. BF buffy coat, WB whole blood, PPP platelet poor plasma
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from the initial value, for factor VIII clothing activity level
when the plasma was frozen more than 1 h after blood
sampling [21].
For one of the citrated tube, we used a recent method to
collect platelet and leukocyte-free plasma for thrombin
generation measurement. Following the first centrifugation,
approximately half the citrated plasma volume was col-
lected. We made sure not to aspirate the top surface of the
plasma, where some light platelets may be found, and were
careful not to disturb the buffy coat by aspirating too close
to the platelet layer [22]. This approach prevented plasma
contamination by platelets and leukocytes that could alter
thrombin generation measurement results.
SWITCO65? biobank
After blood collection and processing, we temporarily
stored cryovials at -80 at each participating center
(Fig. 1). Cryovials and PAXgene Blood RNA System tubes
were left in an upright position in their original plastic bag.
A commercial shipping company periodically transported
the samples, packed in dry ice, to the SWITCO65? bio-
bank. While frozen samples were centrally stored at the
SWITCO65? biobank at the Central Laboratory of
Hematology of Lausanne University hospital, SWIT-
CO65? study laboratory analyses were performed at four
different university hospital laboratories.
The biobank was divided into two different sections, for
short-term and long-term storage (Fig. 1). Samples were
stored in the short-term racks according to plans for analysis
and their destinations. Samples were shipped and transit was
tracked securely from one laboratory to another through the
password-secured, web-based database. Because storage
time was limited to 24 months for D-dimers, fibrinogen,
factor IX, antithrombin and protein C, and 18 months for
factor VIII, factor XI and protein S (allowing for 10 %
variation) [23], analyses were performed within 6 months of
collection, in order to reduce variation to \5 % over base-
line for factor VIII, factor XI and protein S [23, 24].
In long-term storage racks, cryovials from each patient
containing 0.5–2.5 ml of different plasma, serum or whole
blood and one RNA blood system tube containing 2.5 ml
were stored at baseline. Additional cryovials taken at the
patient’s 12 months follow-up appointment were subjected
to long-term storage (Fig. 1).
Storing of blood samples
The blood samples from the SWITCO65? study are stored
in a single -80 C freezer at the Central Laboratory of
Hematology of Lausanne University hospital. There will be
approximately 35,000 cryovials, and 1000 PAXgene Blood
RNA System tubes stored in the biobank. The freezer has a
capacity of 793 l (Thermo Fisher, Fisher Scientific, Wohlen,
Switzerland) and is connected to the institution’s generator
system, in case of power failure. To avoid internal temper-
ature variations that may influence the quality of the stored
blood samples, freezer temperature is continuously con-
trolled through a thermal sensor placed inside the freezer
[24].
A specifically trained biobank nurse is in charge of the
reception, management, and storage of the biosamples. The
2nd to 5th digits 
are the patient  
biobank number 
1st digit 
1 = baseline 
2 = 12 months  
6th digit 
refers to the type of 
cryovials : 
1= EDTA-PPP 
2= Heparin-PPP 
3= serum 
4= Citrated-PPP 
5= EDTA-WB 
6= EDTA-BF 
7= RNA tubes 
8th digit 
is a security 
number 
7th digit 
refers to the number of 
available cryovials  
per patient and 
coagulation type 
Label color and text 
vary according to the 
type of cryovial 
T1 
indicates 
baseline  
blood collection 
Fig. 2 Cryovial label and
barcoding. An example of a
prelabeled cryovial with a
cryoresistant label. On the label
is printed an individual 8-digit
European Article Number
(EAN) 8-digit barcode. BF
buffy coat, WB whole blood,
PPP platelet poor plasma
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blood samples received from participating centers were
immediately stored in original plastic bags in the freezer.
The biobank nurse then opened the plastic bag containing
the cryovials, scanned each barcoded cryovial into the
database, and stored the material in boxes (able to hold up
to 81 cryovials per box) and racks according to type of
cryovial (Fig. 1).
SWITCO65? blood analyses
Laboratory analyses were performed in batches at the Uni-
versity hospitals of Lausanne, Bern, Geneva and Zu¨rich. All
analyses of the same type were performed in the same
laboratory.
We distributed the analysis tasks based on the special-
izations of each of the university hospital laboratories.
Using multiple core laboratories increased the speed of
sample analyses and reduced storage time. Quick turnover
ensured the availability of space in the biobank freezer for
samples arriving from the various study sites. Because
cycles of freezing and thawing may degrade DNA and have
a negative impact on the quality of biomarker measure-
ments, laboratory analyses were performed in batches to
avoid freeze–thaw cycles [24, 25]. Unused sample material
was either returned to the study biobank or destroyed
according to existing disposal standards.
SWITCO65? DNA/RNA depository
VTE is a complex disease with genetic components. Her-
itability estimates indicate that ~60 % of disease risk is
genetic [26, 27]. The genome-wide association (GWA)
strategy has recently been applied to thromboembolic
phenotypes, but sample sizes were relatively small [28, 29].
The SWITCO65? study is suited for such an experiment
due to its sample size of 1,003 patients.
Two buffy coat cryovials, one PAXgene Blood RNA
System tube and one EDTA-whole blood sample were
collected at baseline and will be used for RNA/DNA
extraction. The SWITCO65? DNA and RNA depository
was designed to permit both GWA-replication studies and
GWA studies, with the single limitation that 99.8 % of the
study patients were Caucasians. Thus, the results may not
be generalizable to other racial or ethnic groups.
Preliminary results
Between September 8, 2009, and March 31, 2012, a total of
1,863 patients with VTE were screened. We excluded 462
patients (24.8 %) who had at least one exclusion criteria
and 398 patients (21.4 %) who refused to provide informed
consent, our initial study sample thus comprised 1,003
patients (53.8 % of initially screened patients).
Six patients withdrew their consent and did not allow us
to use their data or blood sample, which reduced the
analysable cohort to 997. Nine-hundred-and-five patients
(90.8 %) had blood collected at baseline. The proportion of
patients who agreed to participate in the cohort study but
refused genetic analyses was 6.5 % (65 out of 997).
By October 16, 2012, after an average follow-up time of
512 days, 799 (80.1 %) patients were still actively partic-
ipating, 150 (15.0 %) had died, and 1 (0.1 %) was lost to
follow-up. Forty-seven out of 1,003 (4.7 %) patients had
withdrawn their consent, but only 6 (0.6 %) did not allow
us the use of their data and blood samples for analysis.
By November 2012, 20,802 cryovials had been stored in
the central SWITCO65? biobank and 7,852 vials had
already been sent for subsequent analyses in one of the four
participating laboratories (Lausanne, Zu¨rich, Bern, Geneva)
(Table 1).
Discussion
In this prospective multicenter cohort study of 1,003
elderly patients with acute symptomatic VTE, we observed
that 21.4 % of the screened patients refused to provide
informed consent, whereas very few patients willing to
participate refused genetic testing (6.5 %). Therefore, we
believe that the primary reason for nonparticipation to this
cohort study is not due to biobanking or genetic analyses
but most probably to the high number and complexity of
baseline and follow-up assessments, a known obstacle to
study participation in the elderly [30].
A classical issue concerning biobanks is the establishment
of standard procedures for blood sample collection, process-
ing and storage. While the design and the development of
biobanking procedures has been described for cardiovascular
disease, such as coronary artery disease, [5] and for cancer, [3]
design and development of biobanking procedures in the field
of haemostasis and thrombosis is currently lacking.
Therefore, we have described the entire process of bio-
banking blood samples from a cohort of elderly patients with
acute VTE, beginning with the decision to collect blood, and
ending with the safe storage of samples. We designed and
developed this process to guarantee the highest quality of stored
material and the best conditions for subsequent analyses.
We have established a biobank that includes DNA and
RNA samples, which can be used to study future, yet
unknown, predictors of VTE-related prognosis. We believe
that association studies between genetic variants and different
clinical VTE phenotypes and VTE recurrence, and between
RNA expression levels and phenotypes and VTE recurrence
might improve our understanding of the pathophysiology of
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VTE events. The low dropout rate of 4.8 % and near-com-
plete blood collection are other strengths.
After recruiting, processing and analyzing the blood of more
than 1,000 study participants, we determined that the adopted
methods and technologies were fit-for-purpose and robust.
Additional information about the cohort, i.e. the study protocol,
data collection forms, study progress, ongoing nested projects,
and planned or published articles, can be found on the study
website (www.switco65.ch) or at the study registry Clinical-
Trials.gov (identifier NCT00973596). The Steering Committee
of SWITCO65? encourages national and international col-
laborative research projects related to the SWITCO65? study,
including sharing anonymized data and biological samples.
Requests for access to SWITCO65? data or material should be
submitted to the Steering Committee, using the Subproject
Proposal Form (available at www.switco65.ch or from the
SWITCO65? project manager: marie.mean@insel.ch).
What is known about this topic?
– Biobanking is increasingly common because research-
ers recognize that large samples are often required to
identify the molecular or genetic basis of complex
diseases, such as VTE.
– In the field of haemostasis, many preanalytical vari-
ables influence the results of coagulation assays and
may affect the quality of the subsequent results.
Therefore, methods to limit these factors affecting the
quality of laboratory results should be anticipated when
building a biobank in the field of haemostasis.
What does this paper add?
– We provide the first description of biobanking of blood
for subsequent DNA, RNA, plasma and serum analyses
in the field of haemostasis and thrombosis.
– We recommend a set of ‘‘best practices’’ for the
development of standardized biobanking processes in
the field of haemostasis and thrombosis to guarantee
the best quality of the blood samples stored.
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